Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
VistaGen Therapeutics, Inc. (VTGN) had Normalized Pre-Tax Income of $-13.03M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$1.48M |
|
$-13.03M |
|
-- |
|
$1.48M |
|
$14.82M |
|
$-13.35M |
|
$0.32M |
|
$-13.03M |
|
|
Normalized Pre-Tax Income |
$-13.03M |
$-13.03M |
|
$-13.03M |
|
$-13.03M |
|
$-13.03M |
|
$-13.35M |
|
$-13.43M |
|
42.98M |
|
42.98M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$34.31M |
|
$0.38M |
|
$1.43M |
|
$35.74M |
|
$11.19M |
|
-- |
|
$0.06M |
|
$11.26M |
|
$24.48M |
|
$24.48M |
|
$24.48M |
|
44.38M |
|
| Cash Flow Statement Financials | |
$-14.71M |
|
$0.00M |
|
$0.91M |
|
$30.79M |
|
$16.99M |
|
$-13.80M |
|
$0.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.07 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-904.34% |
|
-904.34% |
|
-- |
|
-882.79% |
|
-882.79% |
|
$-14.71M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
-- |
|
-- |
|
-53.23% |
|
-53.23% |
|
-36.46% |
|
-53.23% |
|
$0.55 |
|
$-0.34 |
|
$-0.34 |
|